These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9485067)

  • 21. Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington's disease.
    Culjkovic B; Stojkovic O; Vojvodic N; Svetel M; Rakic L; Romac S; Kostic V
    J Neurol; 1999 Nov; 246(11):1090-3. PubMed ID: 10631644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride.
    Antonini A; Leenders KL; Reist H; Thomann R; Beer HF; Locher J
    Arch Neurol; 1993 May; 50(5):474-80. PubMed ID: 8489403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease.
    Furtado S; Suchowersky O; Rewcastle B; Graham L; Klimek ML; Garber A
    Ann Neurol; 1996 Jan; 39(1):132-6. PubMed ID: 8572659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease.
    Lawrence AD; Weeks RA; Brooks DJ; Andrews TC; Watkins LH; Harding AE; Robbins TW; Sahakian BJ
    Brain; 1998 Jul; 121 ( Pt 7)():1343-55. PubMed ID: 9679785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microglial activation in presymptomatic Huntington's disease gene carriers.
    Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P
    Brain; 2007 Jul; 130(Pt 7):1759-66. PubMed ID: 17400599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAG repeat number governs the development rate of pathology in Huntington's disease.
    Penney JB; Vonsattel JP; MacDonald ME; Gusella JF; Myers RH
    Ann Neurol; 1997 May; 41(5):689-92. PubMed ID: 9153534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
    Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
    Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography.
    Kishore A; Nygaard TG; de la Fuente-Fernandez R; Naini AB; Schulzer M; Mak E; Ruth TJ; Calne DB; Snow BJ; Stoessl AJ
    Neurology; 1998 Apr; 50(4):1028-32. PubMed ID: 9566390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.
    Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
    Ann Neurol; 1990 Nov; 28(5):614-21. PubMed ID: 1979723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat.
    Ruocco HH; Lopes-Cendes I; Li LM; Santos-Silva M; Cendes F
    Braz J Med Biol Res; 2006 Aug; 39(8):1129-36. PubMed ID: 16906288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease.
    Reuter I; Tai YF; Pavese N; Chaudhuri KR; Mason S; Polkey CE; Clough C; Brooks DJ; Barker RA; Piccini P
    J Neurol Neurosurg Psychiatry; 2008 Aug; 79(8):948-51. PubMed ID: 18356253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorodopa and raclopride PET analysis of patients with Machado-Joseph disease.
    Shinotoh H; Thiessen B; Snow BJ; Hashimoto S; MacLeod P; Silveira I; Rouleau GA; Schulzer M; Calne DB
    Neurology; 1997 Oct; 49(4):1133-6. PubMed ID: 9339702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
    Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
    Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
    Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D
    J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers.
    Pavese N; Politis M; Tai YF; Barker RA; Tabrizi SJ; Mason SL; Brooks DJ; Piccini P
    Neurobiol Dis; 2010 Feb; 37(2):356-61. PubMed ID: 19853661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers.
    Westermark K; Tedroff J; Thuomas KA; Hartvig P; Långström B; Andersson Y; Hörnfeldt K; Aquilonius SM
    Mov Disord; 1995 Sep; 10(5):596-603. PubMed ID: 8552111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET.
    Andrews TC; Brooks DJ
    Mol Med Today; 1998 Dec; 4(12):532-9. PubMed ID: 9866823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetic analysis of receptor binding with positron emission tomography.
    Eriksson L; Farde L; Rosenquist G
    Acta Radiol Suppl; 1991; 376():126-7. PubMed ID: 1666746
    [No Abstract]   [Full Text] [Related]  

  • 40. Elevated brain iron is independent from atrophy in Huntington's Disease.
    Dumas EM; Versluis MJ; van den Bogaard SJ; van Osch MJ; Hart EP; van Roon-Mom WM; van Buchem MA; Webb AG; van der Grond J; Roos RA;
    Neuroimage; 2012 Jul; 61(3):558-64. PubMed ID: 22480728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.